celecoxib has been researched along with Rheumatoid Arthritis in 176 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to compare the efficacy and safety profiles of pelubiprofen with those of celecoxib in patients with rheumatoid arthritis." | 9.19 | Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. ( Baek, HJ; Cho, CS; Choi, IA; Chung, WT; Kang, SW; Kim, HA; Lee, J; Lee, SS; Lee, YA; Lee, YJ; Park, YB; Park, YE; Song, JS; Song, YW; Yoo, WH, 2014) |
| "To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors." | 9.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| "We included randomized controlled trials of oral celecoxib compared with a non-selective NSAID or placebo in rheumatoid arthritis and osteoarthritis patients." | 9.12 | Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. ( Chen, JQ; Cheng, BR; Gao, QY; Li, WH; Liu, JP; Wu, CJ; Xing, JL; Yan, LJ; Zhang, XW; Zhang, YQ, 2021) |
| "The aim of this study was to compare the pain relief and tolerability of SKI306X and celecoxib in patients with RA." | 9.12 | Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007) |
| "To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability." | 9.10 | Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002) |
| "To study the functional status and health-related quality of life (HRQOL) of patients with rheumatoid arthritis (RA) after treatment with celecoxib, compared with placebo and naproxen." | 9.09 | Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib. ( Dedhiya, SD; Fiechtner, JI; Osterhaus, JT; Tindall, EA; Yu, SS; Zhao, SZ; Zhao, WW, 2000) |
| "To test whether celecoxib has efficacy as an anti-inflammatory and analgesic with reduced GI tract mucosal damage compared with conventional nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis." | 9.09 | Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. ( Geis, GS; Graham, DY; Hubbard, RC; Isakson, PC; Kivitz, AJ; Lipsky, PE; Simon, LS; Verburg, KM; Weaver, AL; Yu, SS; Zhao, WW, 1999) |
| "To determine the effects of celecoxib, a specific inhibitor of cyclooxygenase 2 (COX-2) on the renal clearance and plasma pharmacokinetic profile of stable methotrexate (MTX) doses in patients with rheumatoid arthritis (RA)." | 9.09 | Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ( Geis, GS; Harper, KM; Hubbard, RC; Hunt, TL; Karim, A; Tolbert, DS, 1999) |
| "To assess the benefits and harms of celecoxib in people with rheumatoid arthritis." | 8.95 | Celecoxib for rheumatoid arthritis. ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "The efficacy of celecoxib as an analgesic was comparable to that of loxoprofen, whereas serious GI events, including symptomatic ulcers, were significantly less frequent with celecoxib than with loxoprofen in Japanese patients with rheumatoid arthritis (RA) and osteoarthritis (OA) (p = 0." | 8.87 | Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. ( Sakamoto, C; Soen, S, 2011) |
| "The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis." | 8.82 | Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. ( Derry, S; Makinson, GT; McQuay, HJ; Moore, RA, 2005) |
| "To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis." | 8.81 | Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. ( Bradley, MD; Deeks, JJ; Smith, LA, 2002) |
| " Celecoxib, an anti-inflammatory and analgesic agent indicated for the treatment of osteoarthritis and rheumatoid arthritis, is the first cyclooxygenase (COX) inhibitor with well-defined cyclooxygenase-2 (COX-2) specificity." | 8.80 | Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. ( Tindall, E, 1999) |
| "Celecoxib is the first COX-2 specific inhibitor approved for use in osteoarthritis and rheumatoid arthritis." | 8.80 | Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. ( Clemett, D; Goa, KL, 2000) |
| "Current data revealed that ellagic acid counteracted rheumatoid arthritis-evoked testicular histopathologic changes, disrupted sperm characteristics and low gonadosomatic index with comparable efficacy to celecoxib." | 7.91 | Ellagic acid attenuates testicular disruption in rheumatoid arthritis via targeting inflammatory signals, oxidative perturbations and apoptosis. ( Arab, HH; Eid, AH; Fikry, EM; Gad, AM, 2019) |
| "BACKGROUND Literature shows that serum selenium concentration is low in rheumatoid arthritis (RA) patients." | 7.91 | Selenium Nanoparticles Dispersed in Phytochemical Exert Anti-Inflammatory Activity by Modulating Catalase, GPx1, and COX-2 Gene Expression in a Rheumatoid Arthritis Rat Model. ( Lin, Y; Ma, DS; Ren, SX; Yan, H; Zhan, B, 2019) |
| "Celecoxib (CXB), a COX-2 inhibitor, is primarily indicated for long-term treatment of rheumatoid arthritis (RA)." | 7.88 | Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats. ( Goni, VG; Katare, OP; Khuller, GK; Nirbhavane, P; Patil, AB; Sharma, G; Singh, B, 2018) |
| "A prospective, 3-year comparative observational study compared the risk of cardiovascular events in patients with osteoarthritis or rheumatoid arthritis prescribed celecoxib or a nonsteroidal antiinflammatory drug (NSAID)." | 7.80 | Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. ( Chachin, M; Daida, H; Hirayama, A; Ishiguro, N; Kawai, S; Sugioka, T; Tanahashi, N, 2014) |
| "Celecoxib (CEL), a selective cyclooxygenase-2 (COX-2) inhibitor, has been reported to suppress osteoclastogenesis in vitro, reduce levels of bone resorption markers in ovariectomized (OVX) mice, and prevent bone destruction in rheumatoid arthritis (RA) model mice; however, no clinical data has been reported." | 7.80 | Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis. ( Hamada, M; Kawai, H; Nakase, T; Tomita, T; Tsuji, S; Yoshikawa, H, 2014) |
| "We evaluated the effects of concurrent use of methotrexate and celecoxib on silent liver and kidney damages in rheumatoid arthritis (RA) patients." | 7.80 | Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function. ( Lee, SK; Lee, SW; Park, JS; Park, MC; Park, YB, 2014) |
| "We prospectively evaluated the effects of celecoxib (CEL) on the gastrointestinal (GI) tract of rheumatoid arthritis (RA) patients with endoscopically identified GI mucosal injury after therapeutic switching from the long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs)." | 7.78 | Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation. ( Edogawa, S; Hamada, M; Hirata, Y; Iguchi, M; Kawai, H; Miyoshi, H; Nakase, T; Oomae, T; Tomita, T; Tsuji, S; Tsumoto, C; Yoshikawa, H, 2012) |
| "To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care." | 7.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "We describe the case of an aspirin-sensitive asthma patient with a history of anaphylactic reactions to nonsteroidal anti-inflammatory drugs." | 7.71 | Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma. ( Fischer, R; Harrell, K; Marks, F, 2001) |
| "The Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to evaluate the economic and health impact of the recent introduction of celecoxib for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in Sweden." | 7.70 | The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Haglund, U; Svarvar, P, 2000) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Celecoxib would appear to be a useful option for therapy in patients at high risk for NSAID-induced GI toxicity, or in those responding suboptimally to or intolerant of NSAIDs." | 6.47 | Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. ( McCormack, PL, 2011) |
| "Leflunomide has been shown to be equal to or less efficacious than methotrexate, and may be beneficial as a second-line disease-modifying antirheumatic drug (DMARD)." | 6.41 | Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. ( Chong, BS; Lowder, DM; Luong, BT, 2000) |
| "Celecoxib has shown significant equivalent anti-inflammatory and analgesic efficacy and has produced less endoscopically apparent gastrointestinal (GI) ulceration or erosion than have 3 classic NSAIDs." | 6.40 | Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. ( Goldenberg, MM, 1999) |
| " The relative bioavailability (BA) of the M3 and SD6 formulations was also significantly improved as oral bioavailability (167." | 5.56 | Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis. ( Ahn, JB; Choi, JS; Heo, KS; Lee, DH; Myung, CS; Park, JS; Sim, S, 2020) |
| "Twenty-four thousand eighty-one patients who required NSAIDs for osteoarthritis or rheumatoid arthritis (RA) and had increased CV risk randomly received celecoxib, ibuprofen, or naproxen." | 5.51 | Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. ( Bao, W; Davey, DA; Husni, E; Libby, P; Lüscher, TF; Nissen, SE; Obeid, S; Ruschitzka, F; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Xia, F, 2022) |
| "Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms." | 5.40 | Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014) |
| "An observational study of GERD patients with a diagnosis of OA/RA using two separate databases, the IMS Lifelink Health Plan Claims Database (PharMetrics) and Market Scan Claims Database (Medstat) was conducted." | 5.37 | Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis. ( Assaf, AR; Cryer, B; Luo, X; Mardekian, J; Sands, G, 2011) |
| "Celecoxib is a selective cyclooxygenase (COX)-2 inhibitor that is commonly used to reduce the incidence of gastrointestinal (GI) complications in patients with rheumatoid arthritis (RA)." | 5.34 | Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial. ( Choi, SJ; Choi, WH; Hong, SJ; Hur, JW; Kim, BY; Kim, GT; Kim, HS; Kim, SH; Kim, SS; Kim, YS; Lee, MS; Lee, SI, 2020) |
| "Celecoxib is a non-steroidal anti-inflammatory drug that has been demonstrated to induce apoptosis in some cellular systems." | 5.34 | Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts. ( Audo, R; Combe, B; Deschamps, V; Hahne, M; Morel, J, 2007) |
| "Both membranous glomerulopathy and acute interstitial nephritis have been reported to occur following treatment with non-steroidal anti-inflammatory drugs." | 5.32 | Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. ( Appel, GB; D'Agati, VD; Falkowitz, DC; Imaizumi, S; Isom, R; Markowitz, GS; Zaki, M, 2003) |
| "Celecoxib was dominated by diclofenac in average-risk patients." | 5.32 | The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003) |
| "To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)." | 5.27 | Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| " Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b." | 5.27 | Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. ( Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| "In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62 ± 10 years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100-200 mg bid), ibuprofen (600-800 mg tid), or naproxen (375-500 mg bid) with matching placebos in a 1: 1: 1 allocation, to assess the effect on 24-h ambulatory BP after 4 months." | 5.24 | Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) ( Beckerman, B; Borer, JS; Davey, DA; Fayyad, R; Flammer, AJ; Graham, DY; Husni, ME; Iorga, D; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wisniewski, LM; Yeomans, ND, 2017) |
| "Patients aged 60 years and over with osteoarthritis or rheumatoid arthritis, free from established CV disease and taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous nsNSAID." | 5.24 | Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). ( Connolly, E; Findlay, E; Ford, I; Greenlaw, N; Grobbee, DE; Hallas, J; Hawkey, CJ; Hobbs, FDR; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Perez-Gutthann, S; Ralston, SH; Reid, DM; Ritchie, LD; Ruschitzka, F; Scheiman, JM; Walters, MR; Webster, J; Wei, L; Wilson, A, 2017) |
| " The aim of this study was to compare the efficacy and safety profiles of pelubiprofen with those of celecoxib in patients with rheumatoid arthritis." | 5.19 | Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. ( Baek, HJ; Cho, CS; Choi, IA; Chung, WT; Kang, SW; Kim, HA; Lee, J; Lee, SS; Lee, YA; Lee, YJ; Park, YB; Park, YE; Song, JS; Song, YW; Yoo, WH, 2014) |
| "To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors." | 5.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| "We included randomized controlled trials of oral celecoxib compared with a non-selective NSAID or placebo in rheumatoid arthritis and osteoarthritis patients." | 5.12 | Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis. ( Chen, JQ; Cheng, BR; Gao, QY; Li, WH; Liu, JP; Wu, CJ; Xing, JL; Yan, LJ; Zhang, XW; Zhang, YQ, 2021) |
| "The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients." | 5.12 | Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. ( Lefkowith, JL; Verburg, KM; West, CR; Whelton, A, 2006) |
| "The aim of this study was to compare the pain relief and tolerability of SKI306X and celecoxib in patients with RA." | 5.12 | Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. ( Baek, HJ; Cha, HS; Jung, HG; Kang, SW; Kim, HA; Koh, EM; Lee, CK; Lee, EY; Lee, YJ; Song, YW; Suh, Y; Yoo, B, 2007) |
| " In well designed clinical trials of 1-52 weeks' duration in patients with osteoarthritis (OA) or rheumatoid arthritis, the efficacy of oral lumiracoxib 100-400 mg/day in decreasing pain intensity and improving functional status was greater than that with placebo and similar to those with nonselective NSAIDs or celecoxib 200mg once daily." | 5.11 | Lumiracoxib. ( Curran, MP; Lyseng-Williamson, KA, 2004) |
| "To compare celecoxib (800 mg/day, n=1997) with diclofenac (150 mg/day, n=1996) on dyspepsia-related tolerability." | 5.10 | Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. ( Burke, TA; Eisen, GM; Geis, GS; Goldstein, JL; Lefkowith, J; Peña, BM, 2002) |
| "To study the functional status and health-related quality of life (HRQOL) of patients with rheumatoid arthritis (RA) after treatment with celecoxib, compared with placebo and naproxen." | 5.09 | Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib. ( Dedhiya, SD; Fiechtner, JI; Osterhaus, JT; Tindall, EA; Yu, SS; Zhao, SZ; Zhao, WW, 2000) |
| "To test whether celecoxib has efficacy as an anti-inflammatory and analgesic with reduced GI tract mucosal damage compared with conventional nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis." | 5.09 | Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. ( Geis, GS; Graham, DY; Hubbard, RC; Isakson, PC; Kivitz, AJ; Lipsky, PE; Simon, LS; Verburg, KM; Weaver, AL; Yu, SS; Zhao, WW, 1999) |
| "To determine the effects of celecoxib, a specific inhibitor of cyclooxygenase 2 (COX-2) on the renal clearance and plasma pharmacokinetic profile of stable methotrexate (MTX) doses in patients with rheumatoid arthritis (RA)." | 5.09 | Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. ( Geis, GS; Harper, KM; Hubbard, RC; Hunt, TL; Karim, A; Tolbert, DS, 1999) |
| "To determine the upper gastrointestinal (GI) tolerability of celecoxib, naproxen, and placebo in patients with rheumatoid arthritis (RA) and osteoarthritis (OA)." | 5.09 | Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. ( Agrawal, NM; Bensen, WG; Burke, TA; Geis, GS; Makuch, RW; Maurath, CJ; Zabinski, RA; Zhao, SZ, 2000) |
| " In the upper GI endoscopy study, 19% of subjects receiving naproxen (6 of 32) developed gastric ulcers, whereas no ulcers occurred in subjects receiving SC-58635 or placebo." | 5.08 | Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. ( Geis, GS; Hubbard, RC; Isakson, PC; Lanza, FL; Lipsky, PE; Schwartz, BD; Simon, LS; Talwalker, S, 1998) |
| "To assess the benefits and harms of celecoxib in people with rheumatoid arthritis." | 4.95 | Celecoxib for rheumatoid arthritis. ( Fidahic, M; Jelicic Kadic, A; Puljak, L; Radic, M, 2017) |
| "We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in certain chronic pain conditions." | 4.95 | Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. ( Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM, 2017) |
| "The efficacy of celecoxib as an analgesic was comparable to that of loxoprofen, whereas serious GI events, including symptomatic ulcers, were significantly less frequent with celecoxib than with loxoprofen in Japanese patients with rheumatoid arthritis (RA) and osteoarthritis (OA) (p = 0." | 4.87 | Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. ( Sakamoto, C; Soen, S, 2011) |
| "The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis." | 4.82 | Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. ( Derry, S; Makinson, GT; McQuay, HJ; Moore, RA, 2005) |
| "To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis." | 4.81 | Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. ( Bradley, MD; Deeks, JJ; Smith, LA, 2002) |
| " Celecoxib, an anti-inflammatory and analgesic agent indicated for the treatment of osteoarthritis and rheumatoid arthritis, is the first cyclooxygenase (COX) inhibitor with well-defined cyclooxygenase-2 (COX-2) specificity." | 4.80 | Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. ( Tindall, E, 1999) |
| "Celecoxib is the first COX-2 specific inhibitor approved for use in osteoarthritis and rheumatoid arthritis." | 4.80 | Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. ( Clemett, D; Goa, KL, 2000) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis." | 4.80 | The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. ( Geis, GS; Maddrey, WC; Maurath, CJ; Verburg, KM, 2000) |
| "The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis." | 4.80 | Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. ( Geis, GS; Maurath, CJ; Verburg, KM; Whelton, A, 2000) |
| "The goal of the current investigation was to prepare PEGylated Lipova E120 liposomes loaded with celecoxib for the effective treatment of rheumatoid arthritis (RA)." | 3.91 | PEGylated Lipova E120 liposomes loaded with celecoxib: ( Dave, V; Gupta, A; Sharma, S; Singh, P; Tak, K, 2019) |
| "Current data revealed that ellagic acid counteracted rheumatoid arthritis-evoked testicular histopathologic changes, disrupted sperm characteristics and low gonadosomatic index with comparable efficacy to celecoxib." | 3.91 | Ellagic acid attenuates testicular disruption in rheumatoid arthritis via targeting inflammatory signals, oxidative perturbations and apoptosis. ( Arab, HH; Eid, AH; Fikry, EM; Gad, AM, 2019) |
| "BACKGROUND Literature shows that serum selenium concentration is low in rheumatoid arthritis (RA) patients." | 3.91 | Selenium Nanoparticles Dispersed in Phytochemical Exert Anti-Inflammatory Activity by Modulating Catalase, GPx1, and COX-2 Gene Expression in a Rheumatoid Arthritis Rat Model. ( Lin, Y; Ma, DS; Ren, SX; Yan, H; Zhan, B, 2019) |
| "Celecoxib (CXB), a COX-2 inhibitor, is primarily indicated for long-term treatment of rheumatoid arthritis (RA)." | 3.88 | Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats. ( Goni, VG; Katare, OP; Khuller, GK; Nirbhavane, P; Patil, AB; Sharma, G; Singh, B, 2018) |
| "We used the National Health Insurance Service-National Sample Cohort (NHIS-NSC) to investigate patients over 20 years old with osteoarthritis and rheumatoid arthritis who received a single prescription of SKI306X, celecoxib or naproxen at least once from January 1, 2011 through December 31, 2012." | 3.85 | Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis. ( Hyun, MK; Woo, Y, 2017) |
| "Results of the CONDOR study suggest that in osteoarthritis and rheumatoid arthritis patients at elevated risk of gastrointestinal (GI) events, treatment with celecoxib, a cyclooxygenase (COX)-2 selective non-steroidal anti-inflammatory drug (NSAID), demonstrated significantly lower toxicity in the upper and lower (GI) tract when compared to the non-selective NSAID diclofenac plus a proton-pump-inhibitor (PPI), omeprazole." | 3.81 | How to mechanistically explain the CONDOR study data. ( Buttgereit, F; Spies, CM; Stemmler, E, 2015) |
| "A prospective, 3-year comparative observational study compared the risk of cardiovascular events in patients with osteoarthritis or rheumatoid arthritis prescribed celecoxib or a nonsteroidal antiinflammatory drug (NSAID)." | 3.80 | Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. ( Chachin, M; Daida, H; Hirayama, A; Ishiguro, N; Kawai, S; Sugioka, T; Tanahashi, N, 2014) |
| " Celecoxib Outcome Trial (SCOT), a clinical trial investigating the cardiovascular safety of non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis." | 3.80 | Effectiveness of newspaper advertising for patient recruitment into a clinical trial. ( Hapca, A; Jennings, CG; MacDonald, TM; Mackenzie, IS; Wei, L; Wilson, A, 2014) |
| "Celecoxib (CEL), a selective cyclooxygenase-2 (COX-2) inhibitor, has been reported to suppress osteoclastogenesis in vitro, reduce levels of bone resorption markers in ovariectomized (OVX) mice, and prevent bone destruction in rheumatoid arthritis (RA) model mice; however, no clinical data has been reported." | 3.80 | Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis. ( Hamada, M; Kawai, H; Nakase, T; Tomita, T; Tsuji, S; Yoshikawa, H, 2014) |
| "We evaluated the effects of concurrent use of methotrexate and celecoxib on silent liver and kidney damages in rheumatoid arthritis (RA) patients." | 3.80 | Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function. ( Lee, SK; Lee, SW; Park, JS; Park, MC; Park, YB, 2014) |
| "We prospectively evaluated the effects of celecoxib (CEL) on the gastrointestinal (GI) tract of rheumatoid arthritis (RA) patients with endoscopically identified GI mucosal injury after therapeutic switching from the long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs)." | 3.78 | Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation. ( Edogawa, S; Hamada, M; Hirata, Y; Iguchi, M; Kawai, H; Miyoshi, H; Nakase, T; Oomae, T; Tomita, T; Tsuji, S; Tsumoto, C; Yoshikawa, H, 2012) |
| "To compare the incidence of serious gastrointestinal (GI) complications and associated medical costs in a population with either osteoarthritis (OA) or rheumatoid arthritis (RA) enrolled in Medicare plans with celecoxib formulary restrictions versus plans without such restrictions." | 3.77 | Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. ( Ball, AT; Cappelleri, JC; Deminski, MC; Joshi, AV; Louder, AM; Sanchez, RJ, 2011) |
| " This study evaluated average daily doses and costs of rofecoxib and celecoxib and concomitant use of gastroprotective agents (GPAs) in elderly patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in Quebec, prior to the rofecoxib withdrawal." | 3.73 | Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? ( Chabot, I; Hunsche, E; Rahme, E; Toubouti, Y, 2006) |
| "This study assessed prescribing patterns for rofecoxib and celecoxib in the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as differences in prescribing patterns across physician specialties." | 3.72 | An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. ( Kong, SX; Mavros, P; Mitchell, JH; Pellissier, JM; Schnitzer, TJ; Straus, WL; Watson, DJ, 2003) |
| "A total of 3639 patients with rheumatoid arthritis (RA), osteoarthritis, and fibromyalgia starting therapy of celecoxib, rofecoxib, naproxen, or ibuprofen were surveyed at 6-month intervals for up to 2." | 3.72 | Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. ( Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ, 2004) |
| "To investigate the relationship between nonselective nonsteroidal antiinflammatory drugs (NS NSAID), rofecoxib, celecoxib, and risk of edema and blood pressure destabilization in patients with rheumatoid arthritis (RA) and osteoarthritis (OA) receiving ordinary clinic care." | 3.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "To analyse the cost of celecoxib (selective cyclo-oxygenase-2 inhibitor) and conventional NSAID regimens for the treatment of osteoarthritis and rheumatoid arthritis from the perspective of a public health organization in Hong Kong." | 3.71 | Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. ( Chan, FK; Chan, TY; Lau, WH; Lee, KK; You, JH, 2002) |
| "We describe the case of an aspirin-sensitive asthma patient with a history of anaphylactic reactions to nonsteroidal anti-inflammatory drugs." | 3.71 | Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma. ( Fischer, R; Harrell, K; Marks, F, 2001) |
| "To report a case of nonoliguric acute renal failure secondary to use of celecoxib in a patient with rheumatoid arthritis." | 3.71 | Celecoxib-induced nonoliguric acute renal failure. ( Alkhuja, S; Alwarshetty, M; Ibrahimbacha, AM; Menkel, RA, 2002) |
| "The case history is described of an elderly man with rheumatoid arthritis receiving treatment with sulfasalazine and the cyclooxygenase-2 inhibitor celecoxib who presented with severe shortness of breath, cough, and decreased exercise tolerance." | 3.71 | Migratory pulmonary infiltrates in a patient with rheumatoid arthritis. ( Aranda, CP; Cassai, N; Mehandru, S; Sidhu, GS; Smith, RL, 2002) |
| "A population of 6637 patients with rheumatoid arthritis (RA) and osteoarthritis (OA) from the practices of 433 US rheumatologists completed 2 sets of detailed questionnaires concerning (1) the last 6 months in 1998 and (2) the first 6 months of 1999, generally prior to and after the release of celecoxib and rofecoxib." | 3.71 | Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr ( Arguelles, LM; Burke, TA; Flowers, N; Pettitt, D; Wolfe, F, 2002) |
| "The Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to evaluate the economic and health impact of the recent introduction of celecoxib for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in Sweden." | 3.70 | The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Haglund, U; Svarvar, P, 2000) |
| " This work led to the identification of 1i (4-[5-(4-methylphenyl)-3-(trifluoromethyl)- H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis." | 3.69 | Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). ( Bertenshaw, SR; Burton, EG; Carter, JS; Cogburn, JN; Collins, PW; Docter, S; Graneto, MJ; Gregory, SA; Isakson, PC; Koboldt, CM; Lee, LF; Malecha, JW; Miyashiro, JM; Penning, TD; Perkins, WE; Rogers, RS; Rogier, DJ; Seibert, K; Talley, JJ; Veenhuizen, AW; Yu, SS; Zhang, YY, 1997) |
| " The risk score was designed to predict the 1-year occurrence of major toxicity among NSAID users, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality." | 2.90 | Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. ( Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K, 2019) |
| " The outcome was major nonsteroidal anti-inflammatory drug toxicity, including time to first occurrence of major adverse cardiovascular events, important gastrointestinal events, renal events, and all-cause mortality." | 2.84 | The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. ( Borer, JS; Brennan, DM; Husni, ME; Libby, PA; Lincoff, AM; Lϋscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wisniewski, LM; Yeomans, ND, 2017) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Inflammation is a biological function which triggered after the mechanical tissue disruption or from the responses by the incidence of physical, chemical or biological negotiator in body." | 2.61 | Human disorders associated with inflammation and the evolving role of natural products to overcome. ( Kishore, N; Kumar, P; Shanker, K; Verma, AK, 2019) |
| "Osteoarthritis and rheumatoid arthritis are conditions that are associated with significant clinical burden, and impact on patients' functional status and quality of life." | 2.48 | Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. ( Foster, TS; Huelin, R; Mould, JF; Pokora, T, 2012) |
| "Celecoxib would appear to be a useful option for therapy in patients at high risk for NSAID-induced GI toxicity, or in those responding suboptimally to or intolerant of NSAIDs." | 2.47 | Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. ( McCormack, PL, 2011) |
| " Following oral administration, the less lipophilic celecoxib has a lower bioavailability (20-40%) than the other two coxibs (74-100%)." | 2.44 | Clinical use and pharmacological properties of selective COX-2 inhibitors. ( Klotz, U; Shi, S, 2008) |
| " Pregnancy and lactation require precise monitoring of adverse effects on the fetus, neonate and infant, or discontinuation of therapy with the drug." | 2.42 | [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects]. ( Burdan, F; Korobowicz, A, 2003) |
| "Leflunomide has been shown to be equal to or less efficacious than methotrexate, and may be beneficial as a second-line disease-modifying antirheumatic drug (DMARD)." | 2.41 | Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab. ( Chong, BS; Lowder, DM; Luong, BT, 2000) |
| "Treatment with leflunomide results in significantly greater improvement of the signs and symptoms of RA than placebo for up to 2 yr and slows radiographically assessed disease progression." | 2.41 | New and future drug therapies for rheumatoid arthritis. ( Simon, LS; Yocum, D, 2000) |
| " However, NSAIDs cause significant adverse upper gastrointestinal effects, including increased mortality from serious ulcer complications." | 2.41 | Selective inhibitors of COX-2--are they safe for the stomach? ( Giercksky, KE; Haglund, U; Rask-Madsen, J, 2000) |
| " The usual recommended daily dosage of celecoxib is 200 mg (in one or two intakes per day), to be increased up to 400 mg (two intakes per day) if necessary." | 2.41 | [Pharma-clinics. The drug of the month. Celecoxib (Celebrex)]. ( Scheen, AJ, 2001) |
| "Celecoxib and rofecoxib have been used in Norway since 2000." | 2.41 | [A critical evaluation of side effect data on COX-2 inhibitors]. ( Pomp, E, 2002) |
| "Celecoxib was developed as an antiinflammatory and analgesic agent, and has been studied in preclinical studies and in clinical trials." | 2.40 | Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? ( Geis, GS, 1999) |
| "Celecoxib was developed as an anti-inflammatory and analgesic agent, and has been studied in preclinical studies and in clinical trials." | 2.40 | Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect? ( Geis, GS, 1999) |
| "Celecoxib has shown significant equivalent anti-inflammatory and analgesic efficacy and has produced less endoscopically apparent gastrointestinal (GI) ulceration or erosion than have 3 classic NSAIDs." | 2.40 | Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. ( Goldenberg, MM, 1999) |
| "Mechanical hyperalgesia, joint edema, leukocyte recruitment to the joint and damage to cartilage in experimental arthritis and cytotoxicity, spread of disease, phagocytic activity and nitric oxide (NO) and hydrogen peroxide production by macrophages were evaluated." | 1.91 | 1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan. ( B Carvalho, D; Baroni, ACM; Bonfá, IS; Candeloro, L; das Neves, AR; Felipe, JL; Ferreira, GIS; Lencina, JS; Lossavaro, PKMB; Silva-Filho, SE; Souza, MIL; Toffoli-Kadri, MC, 2023) |
| "Herein, we report a case of systemic lupus erythematosus complicated with JA without bone erosion." | 1.72 | Case report: Joint deformity associated with systemic lupus erythematosus. ( Chen, SL; Lin, CS; Xu, Q; Zhang, LY; Zheng, HJ, 2022) |
| " Nanomedicine has played a crucial role in improving the efficacy of treatment by controlling the release of pharmacologically active ingredients to increase bioavailability and achieve uniform and targeted delivery of drug." | 1.62 | Characterization and in vivo evaluation of nanoformulations in FCA induced rheumatoid arthritis in rats. ( Aslam, B; Faisal, MN; Muhammad, F; Siddique, R, 2021) |
| " The relative bioavailability (BA) of the M3 and SD6 formulations was also significantly improved as oral bioavailability (167." | 1.56 | Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis. ( Ahn, JB; Choi, JS; Heo, KS; Lee, DH; Myung, CS; Park, JS; Sim, S, 2020) |
| "Rheumatoid arthritis is a chronic inflammatory disease characterized by overproduction of inflammatory mediators along with undermined oxidative defensive mechanisms." | 1.40 | Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1. ( El-Azab, MF; El-Sayed, RM; Moustafa, YM, 2014) |
| "CDH11 expressing basal-like breast carcinomas and other CDH11 expressing malignancies exhibit poor prognosis." | 1.40 | Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. ( Anastasiadis, PZ; Assefnia, S; Brenner, M; Brown, ML; Byers, SW; Dakshanamurthy, S; Foley, DW; Guidry Auvil, JM; Haigh, D; Hampel, C; Kallakury, B; Shapiro, L; Uren, A, 2014) |
| "An observational study of GERD patients with a diagnosis of OA/RA using two separate databases, the IMS Lifelink Health Plan Claims Database (PharMetrics) and Market Scan Claims Database (Medstat) was conducted." | 1.37 | Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis. ( Assaf, AR; Cryer, B; Luo, X; Mardekian, J; Sands, G, 2011) |
| "Celecoxib is a non-steroidal anti-inflammatory drug that has been demonstrated to induce apoptosis in some cellular systems." | 1.34 | Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts. ( Audo, R; Combe, B; Deschamps, V; Hahne, M; Morel, J, 2007) |
| "Both membranous glomerulopathy and acute interstitial nephritis have been reported to occur following treatment with non-steroidal anti-inflammatory drugs." | 1.32 | Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. ( Appel, GB; D'Agati, VD; Falkowitz, DC; Imaizumi, S; Isom, R; Markowitz, GS; Zaki, M, 2003) |
| "Celecoxib was dominated by diclofenac in average-risk patients." | 1.32 | The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003) |
| "We report a case of quadriparesis secondary to subluxation and disc herniation at C4-C5 level in a young woman with rheumatoid arthritis of short duration." | 1.32 | Quadriparesis in a young female suffering from rheumatoid arthritis. ( Agarwal, N; Gupta, AK; Jain, SK; Yadava, RK, 2003) |
| "Rofecoxib users were at a significantly increased relative risk of new onset hypertension compared with patients taking celecoxib (odds ratio [OR] 1." | 1.32 | Relationship between COX-2 specific inhibitors and hypertension. ( Avorn, J; Levin, R; Schneeweiss, S; Solomon, DH, 2004) |
| "Electrolyte disorders and acute renal failure are observed more frequently in patients with risk factors." | 1.31 | [Renal tolerance of selective inhibitors of cyclooxygenase type 2]. ( Deray, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (10.80) | 18.2507 |
| 2000's | 100 (56.82) | 29.6817 |
| 2010's | 48 (27.27) | 24.3611 |
| 2020's | 9 (5.11) | 2.80 |
| Authors | Studies |
|---|---|
| Penning, TD | 1 |
| Talley, JJ | 1 |
| Bertenshaw, SR | 1 |
| Carter, JS | 1 |
| Collins, PW | 1 |
| Docter, S | 1 |
| Graneto, MJ | 1 |
| Lee, LF | 1 |
| Malecha, JW | 1 |
| Miyashiro, JM | 1 |
| Rogers, RS | 1 |
| Rogier, DJ | 1 |
| Yu, SS | 3 |
| Burton, EG | 1 |
| Cogburn, JN | 1 |
| Gregory, SA | 1 |
| Koboldt, CM | 1 |
| Perkins, WE | 1 |
| Seibert, K | 1 |
| Veenhuizen, AW | 1 |
| Zhang, YY | 1 |
| Isakson, PC | 4 |
| Hashimoto, H | 1 |
| Imamura, K | 1 |
| Haruta, J | 1 |
| Wakitani, K | 1 |
| Kaila, N | 1 |
| Janz, K | 1 |
| DeBernardo, S | 1 |
| Bedard, PW | 1 |
| Camphausen, RT | 1 |
| Tam, S | 1 |
| Tsao, DH | 1 |
| Keith, JC | 1 |
| Nickerson-Nutter, C | 1 |
| Shilling, A | 1 |
| Young-Sciame, R | 1 |
| Wang, Q | 4 |
| Kishore, N | 1 |
| Kumar, P | 1 |
| Shanker, K | 1 |
| Verma, AK | 1 |
| Chen, HJ | 1 |
| Yang, HR | 1 |
| Zhi, Y | 1 |
| Yao, QQ | 1 |
| Liu, B | 1 |
| Naeem, M | 1 |
| Iqbal, T | 1 |
| Nawaz, Z | 1 |
| Hussain, S | 1 |
| Cheng, BR | 1 |
| Chen, JQ | 1 |
| Zhang, XW | 1 |
| Gao, QY | 1 |
| Li, WH | 1 |
| Yan, LJ | 1 |
| Zhang, YQ | 1 |
| Wu, CJ | 1 |
| Xing, JL | 1 |
| Liu, JP | 1 |
| Obeid, S | 1 |
| Libby, P | 4 |
| Husni, E | 1 |
| Wisniewski, LM | 5 |
| Davey, DA | 2 |
| Wolski, KE | 3 |
| Xia, F | 1 |
| Bao, W | 3 |
| Walker, C | 2 |
| Ruschitzka, F | 3 |
| Nissen, SE | 5 |
| Lüscher, TF | 4 |
| Chen, SL | 1 |
| Zheng, HJ | 1 |
| Zhang, LY | 1 |
| Xu, Q | 1 |
| Lin, CS | 1 |
| Felipe, JL | 1 |
| Bonfá, IS | 1 |
| Lossavaro, PKMB | 1 |
| Lencina, JS | 1 |
| B Carvalho, D | 1 |
| Candeloro, L | 1 |
| Ferreira, GIS | 1 |
| das Neves, AR | 1 |
| Souza, MIL | 1 |
| Silva-Filho, SE | 1 |
| Baroni, ACM | 1 |
| Toffoli-Kadri, MC | 1 |
| Dave, V | 1 |
| Gupta, A | 1 |
| Singh, P | 1 |
| Tak, K | 1 |
| Sharma, S | 1 |
| Arab, HH | 1 |
| Gad, AM | 1 |
| Fikry, EM | 1 |
| Eid, AH | 1 |
| Kim, HS | 1 |
| Choi, WH | 1 |
| Kim, BY | 1 |
| Kim, SS | 1 |
| Lee, SI | 1 |
| Kim, SH | 1 |
| Choi, SJ | 1 |
| Kim, GT | 1 |
| Hur, JW | 1 |
| Lee, MS | 1 |
| Kim, YS | 1 |
| Hong, SJ | 1 |
| Choi, JS | 1 |
| Lee, DH | 1 |
| Ahn, JB | 1 |
| Sim, S | 1 |
| Heo, KS | 1 |
| Myung, CS | 1 |
| Park, JS | 2 |
| Siddique, R | 1 |
| Muhammad, F | 1 |
| Aslam, B | 1 |
| Faisal, MN | 1 |
| Raschle, J | 1 |
| Fidahic, M | 1 |
| Jelicic Kadic, A | 1 |
| Radic, M | 1 |
| Puljak, L | 1 |
| Garner, SE | 1 |
| Fidan, D | 2 |
| Frankish, RR | 1 |
| Judd, M | 2 |
| Shea, B | 2 |
| Towheed, T | 2 |
| Tugwell, P | 2 |
| Wells, GA | 1 |
| Woo, Y | 1 |
| Hyun, MK | 1 |
| Neog, MK | 1 |
| Joshua Pragasam, S | 1 |
| Krishnan, M | 1 |
| Rasool, M | 1 |
| Solomon, DH | 6 |
| Husni, ME | 5 |
| Libby, PA | 1 |
| Yeomans, ND | 4 |
| Lincoff, AM | 4 |
| Lϋscher, TF | 1 |
| Menon, V | 3 |
| Brennan, DM | 1 |
| Borer, JS | 4 |
| Eccleston, C | 1 |
| Cooper, TE | 1 |
| Fisher, E | 1 |
| Anderson, B | 1 |
| Wilkinson, NM | 1 |
| Krum, H | 1 |
| Flammer, AJ | 1 |
| Graham, DY | 4 |
| Fayyad, R | 1 |
| Beckerman, B | 1 |
| Iorga, D | 1 |
| Chen, L | 1 |
| Wu, X | 1 |
| Zhong, J | 1 |
| Li, D | 1 |
| Berger, MF | 3 |
| Chen, YR | 1 |
| Hsieh, FI | 1 |
| Chang, CC | 1 |
| Chi, NF | 1 |
| Wu, HC | 1 |
| Chiou, HY | 1 |
| Stevens, T | 1 |
| Vargo, J | 1 |
| Nirbhavane, P | 1 |
| Sharma, G | 1 |
| Singh, B | 1 |
| Khuller, GK | 1 |
| Goni, VG | 1 |
| Patil, AB | 1 |
| Katare, OP | 1 |
| Ren, SX | 1 |
| Zhan, B | 1 |
| Lin, Y | 1 |
| Ma, DS | 1 |
| Yan, H | 1 |
| Shao, M | 1 |
| Wolski, K | 1 |
| Nissen, S | 1 |
| Paynter, N | 1 |
| Krasselt, M | 1 |
| Baerwald, C | 1 |
| Paulissen, SM | 1 |
| van Hamburg, JP | 1 |
| Davelaar, N | 1 |
| Asmawidjaja, PS | 1 |
| Hazes, JM | 1 |
| Lubberts, E | 1 |
| Hirayama, A | 1 |
| Tanahashi, N | 1 |
| Daida, H | 1 |
| Ishiguro, N | 1 |
| Chachin, M | 1 |
| Sugioka, T | 1 |
| Kawai, S | 3 |
| Chang, HY | 1 |
| Tang, FY | 1 |
| Chen, DY | 1 |
| Chih, HM | 1 |
| Huang, ST | 1 |
| Cheng, HD | 1 |
| Lan, JL | 1 |
| Chiang, EP | 1 |
| Hapca, A | 1 |
| Jennings, CG | 1 |
| Wei, L | 2 |
| Wilson, A | 2 |
| MacDonald, TM | 2 |
| Mackenzie, IS | 2 |
| Tsuji, S | 2 |
| Tomita, T | 2 |
| Nakase, T | 2 |
| Hamada, M | 2 |
| Kawai, H | 2 |
| Yoshikawa, H | 2 |
| Inoue, T | 1 |
| Iijima, H | 1 |
| Arimitsu, J | 1 |
| Hagihara, K | 1 |
| Shiraishi, E | 1 |
| Hiyama, S | 1 |
| Mukai, A | 1 |
| Shinzaki, S | 1 |
| Nishida, T | 1 |
| Ogata, A | 1 |
| Tsujii, M | 1 |
| Takehara, T | 1 |
| El-Sayed, RM | 1 |
| Moustafa, YM | 1 |
| El-Azab, MF | 1 |
| Assefnia, S | 1 |
| Dakshanamurthy, S | 1 |
| Guidry Auvil, JM | 1 |
| Hampel, C | 1 |
| Anastasiadis, PZ | 1 |
| Kallakury, B | 1 |
| Uren, A | 1 |
| Foley, DW | 1 |
| Brown, ML | 1 |
| Shapiro, L | 1 |
| Brenner, M | 1 |
| Haigh, D | 1 |
| Byers, SW | 1 |
| Park, MC | 1 |
| Park, YB | 2 |
| Lee, SK | 2 |
| Lee, SW | 1 |
| Choi, IA | 1 |
| Baek, HJ | 2 |
| Cho, CS | 1 |
| Lee, YA | 1 |
| Chung, WT | 1 |
| Park, YE | 1 |
| Lee, YJ | 2 |
| Lee, J | 1 |
| Lee, SS | 1 |
| Yoo, WH | 1 |
| Song, JS | 1 |
| Kang, SW | 2 |
| Kim, HA | 2 |
| Song, YW | 2 |
| Spies, CM | 1 |
| Stemmler, E | 1 |
| Buttgereit, F | 1 |
| Liu, D | 1 |
| Guo, M | 1 |
| Hu, Y | 1 |
| Liu, T | 1 |
| Yan, J | 1 |
| Luo, Y | 1 |
| Yun, M | 1 |
| Yang, M | 1 |
| Zhang, J | 1 |
| Guo, L | 1 |
| Oh, EH | 1 |
| Shin, JM | 1 |
| Hong, JH | 1 |
| Kim, JS | 1 |
| Ro, YS | 1 |
| Ko, JY | 1 |
| Hawkey, CJ | 1 |
| Ford, I | 1 |
| McMurray, JJV | 1 |
| Scheiman, JM | 2 |
| Hallas, J | 1 |
| Findlay, E | 1 |
| Grobbee, DE | 1 |
| Hobbs, FDR | 1 |
| Ralston, SH | 1 |
| Reid, DM | 1 |
| Walters, MR | 1 |
| Webster, J | 1 |
| Ritchie, LD | 1 |
| Perez-Gutthann, S | 1 |
| Connolly, E | 1 |
| Greenlaw, N | 1 |
| Peck, Y | 1 |
| Leom, LT | 1 |
| Low, PFP | 1 |
| Wang, DA | 1 |
| Anderson, GD | 1 |
| Keys, KL | 1 |
| De Ciechi, PA | 1 |
| Masferrer, JL | 1 |
| Bessette, L | 1 |
| Risebrough, N | 1 |
| Mittmann, N | 1 |
| Roussy, JP | 1 |
| Ho, J | 1 |
| Zlateva, G | 1 |
| Kellner, H | 1 |
| Cheung, R | 1 |
| Cheng, TT | 1 |
| Dong, Y | 1 |
| Lin, HY | 1 |
| Lai, K | 1 |
| Lau, CS | 1 |
| Feng, H | 1 |
| Parsons, B | 1 |
| Romero, FI | 1 |
| Martínez-Calatrava, MJ | 1 |
| Sánchez-Pernaute, O | 1 |
| Gualillo, O | 1 |
| Largo, R | 1 |
| Herrero-Beaumont, G | 1 |
| Rahme, E | 2 |
| Bernatsky, S | 1 |
| Chan, FK | 4 |
| Lanas, A | 2 |
| Scheiman, J | 1 |
| Nguyen, H | 2 |
| Goldstein, JL | 4 |
| Page, TH | 1 |
| Turner, JJ | 1 |
| Brown, AC | 1 |
| Timms, EM | 1 |
| Inglis, JJ | 1 |
| Brennan, FM | 1 |
| Foxwell, BM | 1 |
| Ray, KP | 1 |
| Feldmann, M | 1 |
| Sakamoto, C | 1 |
| Soen, S | 1 |
| Cryer, B | 1 |
| Luo, X | 1 |
| Assaf, AR | 1 |
| Sands, G | 1 |
| Mardekian, J | 1 |
| Wilcox, CM | 1 |
| Peura, D | 1 |
| Sands, GH | 1 |
| Louder, AM | 1 |
| Joshi, AV | 1 |
| Ball, AT | 1 |
| Cappelleri, JC | 1 |
| Deminski, MC | 1 |
| Sanchez, RJ | 1 |
| Miyoshi, H | 1 |
| Oomae, T | 1 |
| Tsumoto, C | 1 |
| Hirata, Y | 1 |
| Iguchi, M | 1 |
| Edogawa, S | 1 |
| McCormack, PL | 1 |
| Huelin, R | 1 |
| Pokora, T | 1 |
| Foster, TS | 1 |
| Mould, JF | 1 |
| Hasegawa, M | 1 |
| Horiki, N | 1 |
| Tanaka, K | 1 |
| Wakabayashi, H | 1 |
| Tano, S | 1 |
| Katsurahara, M | 1 |
| Uchida, A | 1 |
| Takei, Y | 1 |
| Sudo, A | 1 |
| Wooltorton, E | 1 |
| Budenholzer, BR | 1 |
| Bianchi, M | 1 |
| Broggini, M | 1 |
| Deeks, JJ | 1 |
| Smith, LA | 1 |
| Bradley, MD | 1 |
| Håkansson, J | 1 |
| Slørdal, L | 1 |
| Wibe, E | 1 |
| Maehlum, S | 1 |
| You, JH | 2 |
| Lee, KK | 2 |
| Chan, TY | 1 |
| Lau, WH | 2 |
| Hochberg, MC | 2 |
| Kusunoki, N | 1 |
| Yamazaki, R | 1 |
| Garner, S | 1 |
| Frankish, R | 1 |
| Wells, G | 1 |
| Akhund, L | 1 |
| Quinet, RJ | 1 |
| Ishaq, S | 1 |
| Hutchins, V | 1 |
| Hutchins, B | 1 |
| Juni, P | 2 |
| Sterchi, R | 1 |
| Dieppe, P | 1 |
| Metcalfe, S | 1 |
| Dougherty, S | 1 |
| McNee, W | 1 |
| Markowitz, GS | 1 |
| Falkowitz, DC | 1 |
| Isom, R | 1 |
| Zaki, M | 1 |
| Imaizumi, S | 1 |
| Appel, GB | 1 |
| D'Agati, VD | 1 |
| Zeidler, H | 1 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Maetzel, A | 1 |
| Krahn, M | 1 |
| Naglie, G | 1 |
| Layton, D | 2 |
| Hughes, K | 2 |
| Harris, S | 2 |
| Shakir, SA | 2 |
| Tsurko, VV | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Ob ukhova, OA | 1 |
| Burdan, F | 1 |
| Korobowicz, A | 1 |
| Ho, JT | 1 |
| Suen, BY | 1 |
| Yung, MY | 1 |
| Lee, VW | 1 |
| Sung, JY | 1 |
| Cha, HS | 2 |
| Ahn, KS | 1 |
| Jeon, CH | 1 |
| Kim, J | 2 |
| Koh, EM | 2 |
| Chiolero, A | 1 |
| Maillard, MP | 1 |
| Burnier, M | 1 |
| LeLorier, J | 1 |
| Fitzsimon, C | 1 |
| Keresteci, M | 1 |
| Stewart, D | 1 |
| Lavoie, F | 1 |
| Gupta, AK | 1 |
| Agarwal, N | 1 |
| Yadava, RK | 1 |
| Jain, SK | 1 |
| Zhao, SZ | 5 |
| Fiechtner, JI | 1 |
| Tindall, EA | 1 |
| Dedhiya, SD | 1 |
| Zhao, WW | 3 |
| Osterhaus, JT | 2 |
| Burian, M | 1 |
| Geisslinger, G | 1 |
| Schnitzer, TJ | 1 |
| Kong, SX | 1 |
| Mitchell, JH | 1 |
| Mavros, P | 1 |
| Watson, DJ | 1 |
| Pellissier, JM | 1 |
| Straus, WL | 1 |
| Wolfe, F | 3 |
| Michaud, K | 1 |
| Burke, TA | 5 |
| Wentworth, C | 1 |
| Makuch, RW | 2 |
| Wigand, R | 1 |
| Wehling, M | 1 |
| Brauer, HG | 1 |
| Stridde, E | 1 |
| Vergin, H | 1 |
| May, M | 1 |
| Zhao, S | 1 |
| Pettitt, D | 2 |
| Schneeweiss, S | 1 |
| Levin, R | 1 |
| Avorn, J | 1 |
| Tran, F | 1 |
| Boggie, DT | 1 |
| Delattre, ML | 1 |
| Schaefer, MG | 1 |
| Morreale, AP | 1 |
| Plowman, BK | 1 |
| Lyseng-Williamson, KA | 1 |
| Curran, MP | 1 |
| Moore, RA | 1 |
| Derry, S | 1 |
| Makinson, GT | 1 |
| McQuay, HJ | 1 |
| Krüger, K | 2 |
| Heum Park, J | 1 |
| Cho Han, D | 1 |
| Hyung Hong, S | 1 |
| Seog Yoon, K | 1 |
| Min Kim, J | 1 |
| Son, KH | 1 |
| Miyazawa, K | 1 |
| Kwon, BM | 1 |
| Hunsche, E | 1 |
| Toubouti, Y | 1 |
| Chabot, I | 1 |
| Shakiba, K | 1 |
| Falcone, T | 1 |
| Whelton, A | 3 |
| Lefkowith, JL | 1 |
| West, CR | 1 |
| Verburg, KM | 5 |
| Lee, EY | 1 |
| Yoo, B | 1 |
| Lee, CK | 1 |
| Suh, Y | 1 |
| Jung, HG | 1 |
| Wall, R | 1 |
| Strickland, C | 1 |
| Jamieson, B | 1 |
| Lo, V | 1 |
| Shi, S | 1 |
| Klotz, U | 1 |
| Audo, R | 1 |
| Deschamps, V | 1 |
| Hahne, M | 1 |
| Combe, B | 1 |
| Morel, J | 1 |
| Lipsky, PE | 3 |
| Simon, LS | 4 |
| Lanza, FL | 1 |
| Hubbard, RC | 3 |
| Talwalker, S | 1 |
| Schwartz, BD | 1 |
| Geis, GS | 10 |
| Miller, JL | 1 |
| Mandell, BF | 1 |
| Arriola, ER | 1 |
| Lee, NP | 1 |
| Andrews, SA | 1 |
| Wallace, CK | 1 |
| Davis, RL | 1 |
| Lefkowith, JB | 2 |
| Pertusi, RM | 1 |
| Goldenberg, MM | 1 |
| Rosenstein, ED | 1 |
| Kushner, LJ | 1 |
| Kramer, N | 1 |
| Weaver, AL | 1 |
| Kivitz, AJ | 1 |
| Karim, A | 1 |
| Tolbert, DS | 1 |
| Hunt, TL | 1 |
| Harper, KM | 1 |
| Tindall, E | 1 |
| Megeff, CE | 1 |
| Strayer, SM | 1 |
| Infante, R | 1 |
| Lahita, RG | 1 |
| Blondon, H | 1 |
| Clemett, D | 1 |
| Goa, KL | 1 |
| Luong, BT | 1 |
| Chong, BS | 1 |
| Lowder, DM | 1 |
| Oliw, E | 1 |
| Wollheim, FA | 1 |
| Kosinski, M | 1 |
| Dedhiya, S | 1 |
| Ware, JE | 1 |
| Bensen, WG | 1 |
| Zabinski, RA | 1 |
| Maurath, CJ | 3 |
| Agrawal, NM | 2 |
| Silverstein, FE | 1 |
| Faich, G | 1 |
| Pincus, T | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Stenson, WF | 1 |
| Burr, AM | 1 |
| Kent, JD | 1 |
| Yocum, D | 1 |
| Brooks, PM | 1 |
| Day, RO | 1 |
| Giercksky, KE | 1 |
| Haglund, U | 2 |
| Rask-Madsen, J | 1 |
| Cannon, GW | 1 |
| Breedveld, FC | 1 |
| Sundy, JS | 1 |
| Marks, F | 1 |
| Harrell, K | 1 |
| Fischer, R | 1 |
| Scheen, AJ | 1 |
| Tive, L | 1 |
| Svarvar, P | 2 |
| Aly, A | 1 |
| Pasero, C | 1 |
| McCaffery, M | 1 |
| Maddrey, WC | 1 |
| Wildy, KS | 1 |
| Wasko, MC | 1 |
| Nasonov, EL | 1 |
| Cleland, LG | 1 |
| James, MJ | 1 |
| Stamp, LK | 1 |
| Penglis, PS | 1 |
| Deray, G | 1 |
| Alkhuja, S | 1 |
| Menkel, RA | 1 |
| Alwarshetty, M | 1 |
| Ibrahimbacha, AM | 1 |
| Eisen, GM | 1 |
| Peña, BM | 1 |
| Lefkowith, J | 1 |
| Pomp, E | 1 |
| Mehandru, S | 1 |
| Smith, RL | 1 |
| Sidhu, GS | 1 |
| Cassai, N | 1 |
| Aranda, CP | 1 |
| Berenbaum, F | 1 |
| Flowers, N | 1 |
| Arguelles, LM | 1 |
| Silas, S | 1 |
| Clegg, DO | 1 |
| Rutjes, AW | 1 |
| Dieppe, PA | 1 |
| Gupta, S | 1 |
| Crofford, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In Vivo Selectivity of Cyclooxygenase Inhibitors in the Oral Surgery Model[NCT00006299] | Phase 2 | 120 participants | Interventional | 1999-12-31 | Completed | ||
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| [NCT00944866] | 30 participants (Anticipated) | Observational | 2008-03-31 | Active, not recruiting | |||
| A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients[NCT01781702] | Phase 3 | 120 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's[NCT00447759] | Phase 4 | 7,297 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At Hig[NCT00141102] | Phase 4 | 4,484 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus[NCT04066348] | Phase 2 | 310 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| The Impact of Musculoskeletal Ultrasound-added to Clinical Evaluations- on Patient Reported Outcomes: A Prospective Study of Rheumatoid Arthritis Patients Classified in Remission/Low Disease Activity (ULTRAPRO)[NCT03228342] | 94 participants (Actual) | Interventional | 2017-05-03 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 0.058 |
| Oral Diclofenac Plus Omeprazole | 0.073 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | ug/dL (Least Squares Mean) |
|---|---|
| Celecoxib | -3.396 |
| Oral Diclofenac Plus Omeprazole | -1.990 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | percent (Least Squares Mean) |
|---|---|
| Celecoxib | -0.306 |
| Oral Diclofenac Plus Omeprazole | -1.425 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | grams (g)/deciliter (dL) (Least Squares Mean) |
|---|---|
| Celecoxib | -0.017 |
| Oral Diclofenac Plus Omeprazole | -0.423 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | microgram (ug)/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 2.517 |
| Oral Diclofenac Plus Omeprazole | 1.952 |
"Subjects rated response to question: Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today? using a 1 to 5 grading scale where 1=very good and 5=very poor." (NCT00141102)
Timeframe: Month 6/Early Termination (ET)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Celecoxib | 0.754 |
| Oral Diclofenac Plus Omeprazole | 0.773 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 2018 |
| Oral Diclofenac Plus Omeprazole | 2023 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 82 |
| Oral Diclofenac Plus Omeprazole | 79 |
A clinically significant decrease from baseline was defined as a fall in hematocrit > = 10 percentage points and/or hemoglobin > = 2 g/dL. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 45 |
| Oral Diclofenac Plus Omeprazole | 123 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 20 |
| Oral Diclofenac Plus Omeprazole | 81 |
CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 25 |
| Oral Diclofenac Plus Omeprazole | 92 |
"Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 132 |
| Oral Diclofenac Plus Omeprazole | 162 |
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 5 |
| Oral Diclofenac Plus Omeprazole | 11 |
"GI AEs were defined using MedDRA SOC Gastrointestinal Disorders but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 114 |
| Oral Diclofenac Plus Omeprazole | 167 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | IU/L (Least Squares Mean) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | -2.689 | -0.901 | -1.151 |
| Oral Diclofenac Plus Omeprazole | 7.455 | 1.490 | 5.213 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | |
|---|---|---|
| History of GD Ulceration (n=395, 400) | No History of GD Ulceration (n=1843, 1846) | |
| Celecoxib | 7 | 13 |
| Oral Diclofenac Plus Omeprazole | 13 | 68 |
GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | 26 | 8 | 13 |
| Oral Diclofenac Plus Omeprazole | 86 | 12 | 27 |
49 reviews available for celecoxib and Rheumatoid Arthritis
| Article | Year |
|---|---|
Human disorders associated with inflammation and the evolving role of natural products to overcome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Products; Cardiovascular | 2019 |
Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: A systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular System; Celecoxib; Hu | 2021 |
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Humans; Myocardial Infarc | 2017 |
WITHDRAWN: Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Humans; Randomized Contro | 2017 |
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Asp | 2017 |
Celecoxib for the treatment of musculoskeletal arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2019 |
Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Japan; Osteoarthritis; Pyrazo | 2011 |
Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Hum | 2011 |
Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies.
Topics: Arthritis, Rheumatoid; Celecoxib; Cost of Illness; Cost-Benefit Analysis; Cyclooxygenase 2 Inhibitor | 2012 |
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I | 2002 |
Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
Topics: Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibito | 2002 |
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Humans; Pyrazoles; Random | 2002 |
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
[Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheuma | 2003 |
[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhi | 2003 |
Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Ce | 2002 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis | 2003 |
Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Drug Industry; Drug Toler | 2005 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cy | 2005 |
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, | 2005 |
Clinical inquiries. Do COX-2 inhibitors worsen renal function?
Topics: Arthritis, Rheumatoid; Celecoxib; Contraindications; Cyclooxygenase 2 Inhibitors; Humans; Kidney; La | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito | 2008 |
Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Ce | 1997 |
Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Topics: Animals; Arthritis, Rheumatoid; Blood Platelets; Celecoxib; Clinical Trials as Topic; Cyclooxygenase | 1999 |
COX 2-selective NSAIDs: biology, promises, and concerns.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Child; | 1999 |
Treatment advances in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; | 1999 |
Cyclooxygenase-2 specificity and its clinical implications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Clinical Trial | 1999 |
Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; | 1999 |
Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
Topics: Animals; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenas | 1999 |
Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 1999 |
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthri | 2000 |
Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.
Topics: Acute Disease; Animals; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Electron Transp | 2000 |
Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2000 |
[New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trial | 2000 |
New and future drug therapies for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rh | 2000 |
Selective inhibitors of COX-2--are they safe for the stomach?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
Efficacy of cyclooxygenase-2-specific inhibitors.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge | 2001 |
COX-2 inhibitors in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Digestive Sys | 2001 |
[Pharma-clinics. The drug of the month. Celecoxib (Celebrex)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2001 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Controlled Clinical Trial | 2000 |
Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal | 2000 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumat | 2001 |
[Celebrex: confirmed effectiveness and safety (new data)].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygena | 2001 |
COX-2 inhibition and thrombotic tendency: a need for surveillance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I | 2001 |
[A critical evaluation of side effect data on COX-2 inhibitors].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[New nonsteroidal antiinflammatory drugs in rheumatoid arthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Gastric Mucosa; Humans; L | 2002 |
An update on specific COX-2 inhibitors: the COXIBs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2001 |
34 trials available for celecoxib and Rheumatoid Arthritis
| Article | Year |
|---|---|
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2022 |
Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Pyrazole | 2020 |
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Drug Therapy, | 2017 |
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito | 2017 |
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement)
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Coronary | 2017 |
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2018 |
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspi | 2018 |
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2019 |
Clinical use of cyclooxygenase inhibitors impairs vitamin B-6 metabolism.
Topics: Animals; Arthritis, Rheumatoid; Celecoxib; Cricetinae; Cross-Sectional Studies; Cyclooxygenase Inhib | 2013 |
Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Capsule Endoscopy; Celecoxib; | 2014 |
Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Ede | 2014 |
Effect of sanhuangwuji powder, anti-rheumatic drugs, and ginger-partitioned acupoint stimulation on the treatment of rheumatoid arthritis with peptic ulcer: a randomized controlled study.
Topics: Acupuncture Points; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Drugs, Chinese Her | 2015 |
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT).
Topics: Acute Coronary Syndrome; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celec | 2017 |
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; China; Comorbidity; Cy | 2010 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; | 2010 |
Nonsteroidal anti-inflammatory drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Experiment | 2010 |
Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
Topics: Adult; Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celeco | 2011 |
The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group.
Topics: Alanine; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; E | 2013 |
Anti-hyperalgesic effects of nimesulide: studies in rats and humans.
Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; | 2002 |
Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; | 2003 |
Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 2000 |
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge | 2004 |
Lumiracoxib.
Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Doubl | 2004 |
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
Topics: Acid-Base Equilibrium; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 2006 |
Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clematis; Cyclooxy | 2007 |
Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Ce | 1997 |
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase Inhibitors | 1998 |
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal | 1999 |
Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cross-Over Studies; Cyclooxygen | 1999 |
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2000 |
Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind Method | 2000 |
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyg | 2000 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Double-Blind | 2002 |
94 other studies available for celecoxib and Rheumatoid Arthritis
| Article | Year |
|---|---|
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Celecoxib; Cyclooxygenase 1; C | 1997 |
4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1)
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzenesulfonates; Cyclooxygenase 1; Cyclooxygenase | 2002 |
Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Art | 2007 |
Evaluation of pyrrolidine-based analog of jaspine B as potential SphK1 inhibitors against rheumatoid arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Relationship, | 2021 |
Preparation, optimization and evaluation of transdermal therapeutic system of celecoxib to treat inflammation for treatment of rheumatoid arthritis.
Topics: Administration, Cutaneous; Arthritis, Rheumatoid; Celecoxib; Emulsions; Humans; Inflammation; Skin A | 2021 |
Case report: Joint deformity associated with systemic lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; Antigens, Nuclear; Arthritis, Rheumatoid; C-Reactive Protein; Celeco | 2022 |
1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Edema; | 2023 |
PEGylated Lipova E120 liposomes loaded with celecoxib:
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Celecoxib; Disease Models, Animal; Humans; | 2019 |
Ellagic acid attenuates testicular disruption in rheumatoid arthritis via targeting inflammatory signals, oxidative perturbations and apoptosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arthritis, Rheumatoid; Caspase 3; Celec | 2019 |
Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Freund's Adjuvant; Inflammation; | 2020 |
Characterization and in vivo evaluation of nanoformulations in FCA induced rheumatoid arthritis in rats.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Catechols; Celecoxib; Di | 2021 |
Evaluation of cardiovascular risk associated with SKI306X use in patients with osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular D | 2017 |
p-Coumaric acid, a dietary polyphenol ameliorates inflammation and curtails cartilage and bone erosion in the rheumatoid arthritis rat model.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Resorption; Cartilage; Celecoxib; Coum | 2017 |
L161982 alleviates collagen-induced arthritis in mice by increasing Treg cells and down-regulating Interleukin-17 and monocyte-chemoattractant protein-1 levels.
Topics: Animals; Ankle Joint; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Cell Differentiatio | 2017 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2018 |
Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Dru | 2018 |
Selenium Nanoparticles Dispersed in Phytochemical Exert Anti-Inflammatory Activity by Modulating Catalase, GPx1, and COX-2 Gene Expression in a Rheumatoid Arthritis Rat Model.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Experimental; Arthritis, Rheumatoid; Cat | 2019 |
Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase/prostaglandin E2 pathway, independent of IL-23.
Topics: Arthritis, Rheumatoid; CD4 Antigens; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 | 2013 |
Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cele | 2014 |
Effectiveness of newspaper advertising for patient recruitment into a clinical trial.
Topics: Advertising; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Humans; Newspapers as Topic | 2014 |
Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone resorption marker in postmenopausal women with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Biomarkers; Bone Resorption; Celecoxib; Cyclooxygenase 2 Inhibitors; Dr | 2014 |
Evening primrose oil and celecoxib inhibited pathological angiogenesis, inflammation, and oxidative stress in adjuvant-induced arthritis: novel role of angiopoietin-1.
Topics: Administration, Oral; Angiopoietin-1; Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Ex | 2014 |
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arthritis, Rheumatoid; Blotting, Western; Breast Neoplas | 2014 |
Concurrent use of methotrexate and celecoxib increases risk of silent liver fibrosis in rheumatoid arthritis patients with subclinical reduced kidney function.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cross-Sectional Studies; Cycloo | 2014 |
How to mechanistically explain the CONDOR study data.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Intestinal Mucosa | 2015 |
Drug-induced bullous Sweet's syndrome by celecoxib.
Topics: Antirheumatic Agents; Arthralgia; Arthritis, Rheumatoid; Biopsy; Blister; Blood Sedimentation; C-Rea | 2016 |
Establishment of an in vitro three-dimensional model for cartilage damage in rheumatoid arthritis.
Topics: Animals; Apoptosis; Arthritis, Rheumatoid; Cartilage, Articular; Celecoxib; Cell Culture Techniques; | 2018 |
Combination therapies that inhibit cyclooxygenase-2 and leukotriene synthesis prevent disease in murine collagen induced arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arthritis, Experiment | 2009 |
Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2009 |
[Rheumatoid arthritis and depression].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antidepressive Agents, Second- | 2009 |
Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Atherosclerosis; Cachexia; Celecoxib; Cyclo | 2010 |
NSAIDs and risk of lower gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Coloni | 2010 |
Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
Topics: Adult; Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2011 |
Impact of Celecoxib restrictions in medicare beneficiaries with arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2011 |
Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 In | 2012 |
[Inflammation-induced pain. How rheumatism patients profit from the proper NSAID choice].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Drug-Related Side E | 2012 |
[Coxib spares the stomach. This is true also for patients with preventive aspirin administration].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Drug Therapy, Co | 2002 |
What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lactones; Middle Aged; Myocardi | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; | 2002 |
[Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition].
Topics: Activities of Daily Living; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxi | 2002 |
[Financial interests characterize published reports on coxiber. Whom can we rely on?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Cel | 2002 |
[Celecoxib and the CLASS study--worse and worse...].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
[Celecoxib and the CLASS study--a statement].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2002 |
Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cele | 2002 |
Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arthritis, Rheumatoid; Celecoxib; Cell Division; | 2002 |
Celecoxib-related renal papillary necrosis.
Topics: Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhi | 2003 |
COX-2 inhibitors: new drugs for the management of pain and inflammation.
Topics: Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid | 2001 |
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Data Interpretation, Stat | 2003 |
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Gastrointestinal Diseases | 2003 |
Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Fema | 2003 |
[When the cardiac patient with arthritis needs aspirin and NSAID: how to protect the stomach?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Celecoxi | 2003 |
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D | 2003 |
[Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2003 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Cel | 2003 |
Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2003 |
Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cele | 2003 |
Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes.
Topics: Arthritis, Rheumatoid; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy | 2004 |
Drug utilization review of celecoxib in Ontario.
Topics: Aged; Arthritis, Rheumatoid; Celecoxib; Cost Control; Cyclooxygenase Inhibitors; Drug Utilization Re | 2003 |
Quadriparesis in a young female suffering from rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cervical Vertebrae; Chloroquine; Cycl | 2003 |
An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2003 |
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services | 2004 |
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh | 2004 |
[Celecoxib in the symptomatic treatment of active osteo- or rheumatoid arthritis. Results of a post-marketing surveillance].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2004 |
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox | 2004 |
Relationship between COX-2 specific inhibitors and hypertension.
Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Hum | 2004 |
[Selective cox-2 inhibitors. Better tolerance than NSAID plus antacid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2004 |
Differential regulation of anti-inflammatory proteins in human rheumatoid synoviocyte MH7A cell by celecoxib and ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cell Line; Electrophoresi | 2006 |
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
Topics: Aged; Aged, 80 and over; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; Costs and Cost Analysi | 2006 |
Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 I | 2006 |
Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts.
Topics: Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arthritis, Rheumatoid; Caspase 3; Ce | 2007 |
Celecoxib for arthritis.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyg | 1999 |
Celecoxib approved as NSAID with some concessions on class warning.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 1999 |
New drug overview. Celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Osteoarthritis; Pyrazoles | 1999 |
Celecoxib: a COX-2 inhibitor.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; | 1999 |
Novel therapeutic options bring hope to patients with rheumatic conditions--and to the physicians who treat them.
Topics: Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval | 1999 |
Rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aurothioglucos | 1999 |
COX-2 inhibitors. Magic bullets or merely mortal?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cycloox | 2000 |
Celecoxib for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 2000 |
COX-2 inhibitors.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenas | 2000 |
[Rheumatism therapy, from the economic viewpoint. COX-2 inhibitor as cost saving drug].
Topics: Arthritis, Rheumatoid; Celecoxib; Cost Savings; Cyclooxygenase Inhibitors; Drug Costs; Germany; Lact | 2000 |
Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Asthma; | 2001 |
Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost of Illness; Cost-Ben | 2000 |
The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost of Illness; Cost-Ben | 2000 |
Selective COX-2 inhibitors.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; | 2001 |
[Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroida | 2001 |
[Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 2001 |
Celecoxib-induced nonoliguric acute renal failure.
Topics: Acute Kidney Injury; Adult; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Female; Hum | 2002 |
[Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; | 2001 |
Migratory pulmonary infiltrates in a patient with rheumatoid arthritis.
Topics: Aged; Airway Obstruction; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh | 2002 |
[Symptomatic therapy of arthrosis and rheumatoid arthritis. Who will benefit from Coxib?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Humans; Middle Aged | 2002 |
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr
Topics: Aged; Arthritis, Rheumatoid; Bias; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2; | 2002 |
Selective COX-2 inhibition.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors | 1999 |
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase | 2002 |